Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice

Cancer Research

Volumn 62, Issue 13, 2002, Pages 3711-3715

  Goto, Hisatsugu ^a   Yano, Seiji ^a   Zhang, Helong ^a   Matsumori, Yuka ^a   Ogawa, Hirohisa ^a   Blakey, David C ^b   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; AURISTATIN PE; CISPLATIN; COMBRETASTATIN A4; DOCETAXEL; ETOPOSIDE; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TAIL; TARGET CELL DESTRUCTION; TUMOR BLOOD FLOW; TUMOR NECROSIS; VASCULAR ENDOTHELIUM; XENOGRAFT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL DIVISION; ENDOTHELIUM, VASCULAR; GROWTH INHIBITORS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS;

EID: 0036644835     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Metastasis results from preexisting variant cells within a malignant tumor
2. Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements
3. Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735b melanoma cells from producing metastases
4. Seminars in medicine of the Beth Israel Hospital. Boston. Clinical applications of research on angiogenesis
5. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
6. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
7. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy
8. Development of matrix metalloproteinase inhibitors in cancer therapy
9. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
10. Vascular attack as a therapeutic strategy for cancer
11. The implications of angiogenesis for the biology and therapy of cancer metastasis
12. Tumor vasculature as a target for cancer therapy
13. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
14. Combretastatin A-4. An agent that displays potent and selective toxicity toward tumor vasculature
15. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death
16. ZD6126: A new agent causing selective damage of tumor vasculature
17. Production of experimental malignant effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells
18. Cross-linked envelope-related markers for squamous differentiation in human lung cancer cell lines
19. Rapid colorimetric assay for cell viability: Application to the quantitation of cytotoxic and growth inhibitory lymphokines
20. The distribution of secondary growth in cancer of the breast
21. Macrophage colony-stimulating factor gene transduction into human lung cancer cells differentially regulates metastasis formations in various organ microenvironments of natural killer cell-depleted SCID mice
22. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
23. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex
24. Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy
25. Effects of PTK787/ZK222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
26. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors
27. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells
28. A tetracycline-responsive promoter system reveals the role of a secreted binding protein of FGFs during the early phase of tumor growth
29. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
30. Cancer dormancy: Opportunities for new therapeutic approaches
31. New perspectives in clinical oncology from angiogenesis research
32. Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies
33. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy
34. Anti-tumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models
35. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
36. Phase I study of weekly intravenous Combretastatin A4 phosphate (CA4P): Pharmacokinetics and toxicity